A recent Endocrinology digest,
as sent to subscribers

Study Type: Prespecified analysis of a randomized controlled trial

Key Question: Does automated insulin delivery (closed-loop system) improve glycaemic control during labour and early postpartum period compared to standard care in women with type 1 diabetes?

Key Findings:

• During the 24 hours before delivery, closed-loop users achieved 79.6% vs 64.8% time in pregnancy-specific glucose range (63-140 mg/dL), with adjusted difference of 13.2 percentage points (95% CI 5.2-21.2)
• In the first postpartum week, closed-loop group had less hypoglycaemia: 1.7% vs 3.2% time <70 mg/dL (adjusted difference -1.8 percentage points, 95% CI -0.9 to -2.7)
• Intravenous insulin was required in only 2% of closed-loop vs 45% of standard care participants during labour

Clinical Relevance: These results support using closed-loop systems throughout the entire perinatal period in type 1 diabetes, potentially reducing the complexity of intrapartum glucose management in UK maternity services.

Limitations: Small sample size with only 44 participants analysed in the closed-loop group.

Study Type: Randomized controlled trial

Key Question: Does a 12-month peer mentor behavioral intervention improve glycemic control and transition outcomes in young adults with type 1 diabetes transferring from pediatric to adult care?

Key Findings:

• No significant differences in HbA1c, self-management behaviors, or time to adult care transfer between intervention and usual care groups (n=100, ages 17-25)
• Significant improvements in diabetes-specific quality of life and reduced diabetes distress at 12 months in the intervention group
• High participant satisfaction with the peer mentor intervention despite limited clinical benefits

Clinical Relevance: Addresses a critical NHS transition period where young adults with T1DM face high rates of disengagement and deteriorating glycemic control, though this intervention shows limited clinical effectiveness.

Limitations: Reduced sample size due to COVID-19 pandemic may have limited statistical power to detect meaningful differences between groups.

Study Type: Nationwide registry cohort study

Key Question: Does diabetes affect the incidence and anatomical pattern of femoral fractures in older adults?

Key Findings:

• Type 1 diabetes significantly increased fracture rates (ST/FS IRR 2.53, hip IRR 2.17) compared to non-diabetic controls, with associations persisting after age adjustment
• Type 2 diabetes showed modest increases in fracture rates (ST/FS IRR 1.08, hip IRR 1.06) that became non-significant after age adjustment
• Both diabetes types were associated with higher odds of subtrochanteric/femoral shaft fractures relative to hip fractures (T1DM OR 1.14, T2DM OR 1.05)

Clinical Relevance: UK endocrinologists should recognise that patients with type 1 diabetes have substantially elevated femoral fracture risk requiring enhanced bone health monitoring and fracture prevention strategies.

Limitations: Registry-based design cannot establish causality or account for unmeasured confounders such as medication use or bone density measurements.

Study Type: Narrative review

Key Question: How does renal lipotoxicity contribute to diabetic kidney disease and what therapeutic strategies can target this mechanism?

Key Findings:

• Dysregulated lipid transporters (CD36, FATPs, FABPs) and impaired fatty acid oxidation via PPARα downregulation drive toxic lipid accumulation in kidney cells
• Multiple renal cell types (podocytes, tubular epithelial cells, mesangial cells) undergo lipid-induced injury leading to mitochondrial dysfunction, oxidative stress, and fibrosis
• Therapeutic targets include SGLT2 inhibitors, GLP-1 receptor agonists, statins, fibrates, and ABCA1 inducers to restore renal lipid homeostasis

Clinical Relevance: This provides mechanistic rationale for using established diabetes medications (SGLT2 inhibitors, GLP-1 agonists) and lipid-lowering therapies as renoprotective agents in UK patients with diabetic kidney disease, supporting integrated cardiovascular-kidney-metabolic care pathways.

Limitations: As a narrative review, it does not provide systematic evaluation of evidence quality or quantitative analysis of therapeutic efficacy.

Study Type: Longitudinal cohort study

Key Question: Does earlier transfer from pediatric to adult type 1 diabetes services affect glycemic outcomes compared to later transfer?

Key Findings:

• Early transferers (before age 18) had higher HbA1c at first adult visit (9.3% vs 8.8%, p=0.01) and longer gaps between services (13.5 vs 8.1 months, p<0.001)
• Younger transfer age was independently associated with higher adult-service HbA1c (β=-0.15, 95% CI -0.30 to -0.002, p=0.047) alongside socioeconomic disadvantage
• Early transferers were more socioeconomically disadvantaged, suggesting confounding factors

Clinical Relevance: This challenges current UK practice where many services transfer patients at 16-17 years, suggesting delayed transfer until 18+ may improve glycemic outcomes and service continuity.

Limitations: Observational design cannot establish causation, and confounding by socioeconomic factors may explain the association rather than transfer timing alone.

Study Type: Retrospective cohort study

Key Question: Does restricted weight gain (<5 kg) during pregnancy improve perinatal outcomes in women with type 2 diabetes?

Key Findings:

• Weight gain <5 kg (occurring in 34% of 954 pregnancies) reduced risk of large-for-gestational-age births (aOR 0.42, 95% CI 0.29-0.59) and hypertensive disorders (aOR 0.56, 95% CI 0.42-0.75)
• Additional benefits included reduced NICU admissions (aOR 0.74) and caesarean deliveries (aOR 0.66)
• No significant increase in small-for-gestational-age births or preterm delivery with restricted weight gain

Clinical Relevance: Challenges current UK pregnancy weight gain guidance for women with type 2 diabetes, suggesting restricted weight gain may improve maternal and neonatal outcomes without apparent harm.

Limitations: Retrospective design cannot establish causation, and findings may reflect pre-existing patient characteristics rather than weight gain itself.

Study Type: Narrative review

Key Question: What emerging biomarkers beyond aldosterone and renin could improve diagnosis and subtyping of primary aldosteronism?

Key Findings:

• Steroidomic profiling shows promise for both diagnosing PA and distinguishing unilateral from bilateral disease
• Proteomic, metabolomic, and transcriptomic approaches are revealing molecular signatures that could complement traditional hormone assays
• End-organ damage markers may serve as indicators of disease burden and treatment response

Clinical Relevance: These emerging biomarkers could address current diagnostic limitations in PA screening and subtyping, potentially reducing reliance on technically demanding adrenal vein sampling and improving patient selection for surgical intervention.

Limitations: This is a narrative review synthesising research rather than presenting original data on biomarker performance.

Study Type: Narrative review

Key Question: How do nuclear receptors contribute to sepsis pathophysiology and could they represent therapeutic targets?

Key Findings:

• Systemic inflammation in sepsis suppresses multiple nuclear receptors, contributing to immune dysfunction and metabolic failure
• Key nuclear receptors affected include hepatocyte nuclear factor 4α, retinoid X receptor, and glucocorticoid receptor
• Targeting these nuclear receptors could potentially restore immune-metabolic balance and improve patient outcomes

Clinical Relevance: This review identifies nuclear receptors as potential therapeutic targets in sepsis, which currently lacks specific treatments and remains a major cause of mortality in UK critical care units.

Limitations: As a narrative review, it does not provide systematic analysis of evidence quality or quantitative assessment of therapeutic potential.